Preparation method and application of asymmetric urea small molecule compound and derivatives

By preparing asymmetric urea small molecule compounds, the toxic side effects and drug resistance problems of existing babescis disease treatment drugs are solved, and a safe and effective treatment plan is provided, with insecticidal effects and simplified the synthesis process.

CN117720469BActive Publication Date: 2024-11-19SOUTHWEST UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311712914.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-13
Publication Date
2024-11-19
Estimated Expiration
2043-12-13

AI Technical Summary

Technical Problem

The existing treatment drugs for babescis disease have obvious toxic and side effects and parasite resistance, and limited treatment options, and urgently need safe and effective alternative drugs and new treatment plans.

Method used

Provide a method for preparing asymmetric urea small molecule compounds and their derivatives, including mixing and stirring compound A, ethylenediamine, tert-butanol, adding Na2CO3 and I2, heating reaction, then reacting with palladium carbon, and finally in isocyanate Heating to obtain asymmetric urea small molecule compounds with Babesworm-killing effect.

Benefits of technology

The preparation method has short synthetic routes, mild reaction conditions, rich raw materials and easy to obtain, simple operation and post-treatment, and compounds have insecticidal effects on Babesworm, providing a new treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117720469B_ABST
    Figure CN117720469B_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of asymmetric urea therapeutic compounds, and discloses a method for preparing an asymmetric urea small molecule compound and a derivative and an application thereof. The method for preparing the asymmetric urea small molecule compound and a derivative comprises the following steps: mixing compound A, ethylenediamine, and tert-butyl alcohol, adding Na2CO3 and I2, heating the reaction, and purifying the reaction product mixture to obtain a nitro compound; dissolving the nitro compound, adding palladium carbon, reacting, filtering the reaction product mixture, evaporating, and obtaining an amine compound; adding the corresponding isocyanate to an amine compound and triethylamine N,N-dimethylformamide solution, heating the reaction, and purifying the reaction product mixture to obtain an asymmetric urea small molecule compound and a derivative thereof. The present invention provides a class of asymmetric urea small molecule compounds and derivatives having novel structures and having the effect of killing Babesia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of asymmetric urea therapeutic compounds, and in particular to a preparation method and application of an asymmetric urea small molecule compound and derivatives. Background Art

[0002] Babesiosis is a zoonosis caused by Babesia parasites living in red blood cells. It is transmitted by hard ticks. Its pathogenic mechanism is mainly the lysis of infected red blood cells leading to hemolytic anemia, which can further lead to organ failure or even death under special circumstances. Babesia uses mammals as intermediate hosts and ticks as final hosts. It needs to switch between two hosts to complete its life cycle. Babesia can enter the tick body through the blood sucking of female ticks. After developing in the tick body, it is transmitted to the offspring of the tick through eggs, and then transmitted by the tick's different growth stages (larvae, nymphs, and adults). This type of pathogen has a wide range of hosts. It can not only parasitize a variety of vertebrates and invertebrates, but some Babesia can also infect humans. The more effective and commonly used drugs for the treatment of babesiosis are mainly imidazopyrimidine, triazoguanidine, azithromycin, atovaquone, clindamycin, etc. The pathogenic life cycle of babesiosis is complex, and most of them have recurrent infections. Most of the chemical drugs commonly used to treat babesiosis have a strong inhibitory effect on babesiosis, but the use of drugs is hindered by the limited treatment options for the disease. Imidazole urea, also known as imidocarb and diimidazole urea, is a symmetrical urea compound. It was first introduced in Switzerland in 1969. Imidazole urea is not absorbed orally. Most of the clinically used is dipropionic acid imidazole urea injection, but the drug has high liver and kidney toxicity and a long withdrawal period. Triazoline, also known as Bernier and Xuechongjing, is an aromatic double amidine drug. my country synthesized the drug in the early 1960s and was subsequently approved for the treatment of animal piroplasmosis. Triazoline has a good insecticidal effect, but it is highly toxic: for example, cattle are severely poisoned at 25mg / kg, and buffaloes will have toxic reactions or even death if they are continuously used. The drugs commonly used to treat babesiosis currently have obvious toxic and side effects and parasites develop drug resistance. Therefore, safe and effective alternative drugs and new treatment plans are urgently needed. Summary of the invention

[0003] In order to solve the above technical problems, the present invention provides a method for preparing an asymmetric urea small molecule compound and a derivative thereof, comprising the following steps:

[0004] Step (1) Compound A, ethylenediamine and tert-butanol are mixed and stirred, Na2CO3 and I2 are added, and the mixture is heated for reaction, and the reaction product mixture is purified to obtain a nitro compound;

[0005] Step (2) dissolving the nitro compound, adding palladium on carbon, reacting, filtering the reaction product mixture, and evaporating to obtain an amine compound;

[0006] Step (3) adding the corresponding isocyanate to the N,N-dimethylformamide solution of the amine compound and triethylamine, heating the mixture for reaction, and purifying the reaction product to obtain an asymmetric

[0007] Derivatives of urea small molecule compounds, the general structural formula is:

[0008]

[0009] Among them, R 1 Including any one of halogen, hydrogen, and alkoxy; R 2 It includes any one of halogen, alkyl, alkoxy and cyano, located at the para or meta position of the benzene ring.

[0010] Preferably, in step (1), the general structural formula of compound A is: The general structural formula of nitro compounds is

[0011] Preferably, in the step (1), the usage ratio of compound A, ethylenediamine, Na2CO3 and I2 is (2 mmol):(1.1 equivalents):(3 equivalents):(1.25 equivalents).

[0012] Preferably, in step (1), the mixing and stirring time is 30 minutes; the heating reaction conditions are: heating to 70° C. and stirring the reaction for 3 hours.

[0013] Preferably, in step (1), the reaction product mixture purification method is as follows: the reaction product mixture system is first decompressed to remove the reaction solvent tert-butanol, then ethyl acetate is added, and insoluble matter is removed by ultrasonication and filtration, and the organic layer is washed with saturated Na2SO3 aqueous solution and brine, and dried with anhydrous MgSO4, and then purified by column chromatography.

[0014] Preferably, in step (2), the solvent for dissolving the nitro compound comprises methanol; the amount of palladium carbon added is 5 wt%; reaction conditions: the reaction system is deoxygenated, H2 is added through a balloon, and the reaction is carried out at room temperature overnight; filtering method: the reaction product mixture is filtered through diatomaceous earth.

[0015] Preferably, in step (3), the general structural formula of the isocyanate is

[0016] Preferably, in step (3), the heating reaction conditions are: heating to 60° C. and stirring for 5 h; the usage ratio of the amine compound, triethylamine, and isocyanate is (1 mmol): (2 equivalents): (1 equivalent)

[0017] Preferably, in the step (3), the reaction product mixture is purified by a method as follows: after the reaction is completed by thin layer chromatography, the reaction product mixture is extracted with dichloromethane, the organic phase is washed with saturated brine and dried over anhydrous MgSO4, the organic phase is distilled under reduced pressure to obtain a crude product, and the crude product is purified by column chromatography.

[0018] The asymmetric urea small molecule compound and derivatives are used for treating babesiosis.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] The present invention provides a class of novel asymmetric urea small molecule compounds and derivatives thereof, and the preparation method thereof has the advantages of short synthesis route, mild reaction conditions, abundant and readily available raw materials, simple operation and post-treatment, etc. The asymmetric urea small molecule compounds and derivatives thereof have the effect of killing Babesia.

[0021] The asymmetric urea small molecule compound and derivatives are used for treating babesiosis.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention provides a class of novel asymmetric urea small molecule compounds and derivatives thereof, and the preparation method thereof has the advantages of short synthesis route, mild reaction conditions, abundant and readily available raw materials, simple operation and post-treatment, etc. The asymmetric urea small molecule compounds and derivatives thereof have the effect of killing Babesia. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 It is a schematic diagram of the synthesis of the asymmetric urea small molecule compounds and derivatives of the present invention. DETAILED DESCRIPTION

[0025] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0026] Example 1 Preparation of N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-fluorophenyl)amino]methaneamide:

[0027] Step (1) 3-nitrobenzaldehyde (2 mmol) and ethylenediamine (1.1 equivalents) were mixed with tert-butanol and stirred for 30 minutes, then Na2CO3 (3 equivalents) and I2 (1.25 equivalents) were added to the mixture, and the reaction temperature was raised to 70°C and stirring was continued for 3 hours. After the reaction was completed, the reaction solvent tert-butanol was removed under reduced pressure, ethyl acetate was added to the mixture, and insoluble matter was removed by ultrasonication and filtration. The organic layer was washed with saturated Na2SO3 aqueous solution and brine, and dried over anhydrous MgSO4. The resulting mixture was purified by column chromatography to obtain 2-(3-nitrophenyl)-4,5-dihydro-3H-imidazole, the chemical structure of which is as follows:

[0028]

[0029] 1 H NMR (400MHz, Chloroform-d) δ8.51(t,J=2.0Hz,1H),8.24(J=8.3,2.3,1.1Hz,1H),8.11(dt,J=7.8,1.4Hz,1H),7.54(t,J=8.0Hz,1H),3.79(s,4H).

[0030] Step (2) The 2-(3-nitrophenyl)-4,5-dihydro-3H-imidazole obtained in the previous step is dissolved in methanol, and then 5 wt% palladium carbon is added, the reaction container is deoxygenated, and H2 is added through a balloon, and the reaction is carried out at room temperature overnight. The resulting mixture is filtered through diatomaceous earth, and the filtrate is evaporated to obtain 5-(4,5-dihydro-3H-imidazole-2-yl)aniline, the chemical structure of which is as follows:

[0031]

[0032] 1 H NMR (400MHz, DMSO-d6) δ7.17(t,J=7.8Hz,1H),7.09–7.00(m,2H),6.82(dd,J=7.9,2.2Hz,1H),5.46(s,2H),3.80(s,4H).

[0033] Step (3) To a stirred DMF solution of 5-(4,5-dihydro-3H-imidazol-2-yl)aniline (1 mmol) and triethylamine (2 equivalents) was added the corresponding 4-fluorophenyl isocyanate (1 equivalent), and the mixture was stirred at 60° C. for 5 hours. After the reaction was completed by thin layer chromatography, the mixture was extracted with dichloromethane, the organic phase was washed with saturated brine and dried over anhydrous MgSO4, and the organic phase was distilled under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-fluorophenyl)amino]methaneamide, the chemical structure of which is as follows:

[0034]

[0035] 1 H NMR(400MHz,DMSO-d6)δ10.61(s,1H),9.82(s,1H),9.74(s,1H),8.10(d,J=2.2Hz,1H),7 .73(dd,J=7.3,2.2Hz,1H),7.57–7.47(m,4H),7.14(t,J=8.9Hz,2H),3.99(s,4H).ESI-MS m / z:[M+1]calculated for C 16 H 15 FN4O:298.3;found:298.9.

[0036] Example 2 Preparation of N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-fluorophenyl)amino]methaneamide:

[0037] The difference between this embodiment and embodiment 1 is that: in step (3), 3-fluorophenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0038] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0039] The chemical structure of the obtained N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-fluorophenyl)amino]methaneamide is as follows:

[0040]

[0041] 1 H NMR (400MHz, DMSO-d6) δ10.52(s,1H),9.87(s,1H),9.80(s,1H),8.11(d,J=1.9Hz,1H),7.75–7.68(m,1H),7.61– 7.48(m,3H),7.32(h,J=7.1Hz,1H),7.13(dd,J=8.1,1.9Hz,1H),6.80(td,J=8.5,2.5Hz,1H),4.00(s,4H).ESI-MS m / z:[M+1]calculated forC 16 H 15 FN4O:298.3;found:298.9.

[0042] Example 3 Preparation of 1-[(4-chlorophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide:

[0043] The difference between this embodiment and embodiment 1 is that: in step (3), 4-chlorophenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0044] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0045] The chemical structure of the obtained 1-[(4-chlorophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide is as follows:

[0046]

[0047] 1 H NMR (400MHz, DMSO-d6) δ10.48(s,1H),9.88(d,J=5.6Hz,2H),7.73(dt,J=7.7,1.9Hz,1H),7.59–7.47(m,4H),7.37–7.32(m,2H),4.00(s,4H).ESI-MS m / z:[M+1]calculated for C 16 H 15 ClN4O:314.7;found:314.9.

[0048] Example 4 Preparation of 1-[(3-chlorophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide:

[0049] The difference between this embodiment and embodiment 1 is that: in step (3), 3-chlorophenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0050] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0051] The chemical structure of the obtained 1-[(3-chlorophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide is as follows:

[0052]

[0053] 1H NMR (400MHz, DMSO-d6) δ10.48(s,1H),10.03(s,1H),9.93(s,1H),8.11(d,J=2.3Hz,1H),7.72(d t,J=9.6,2.2Hz,2H),7.54(s,2H),7.30(s,2H),7.03(dt,J=6.8,2.2Hz,1H),3.99(s,4H).ESI-MS m / z:[M+1]calculated for C 16 H 15 ClN4O:314.7;found:314.9.

[0054] Example 5 Preparation of N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-methylphenyl)amino]methaneamide

[0055] The difference between this embodiment and embodiment 1 is that 4-methylphenyl isocyanate is used instead of 4-fluorophenyl isocyanate in step (3); the other steps in this embodiment are the same as those in embodiment 1 and are not described again.

[0056] The chemical structure of the obtained N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-methylphenyl)amino]methaneamide is as follows:

[0057]

[0058] 1 H NMR (400MHz, DMSO-d6) δ10.40(s,1H),9.78(s,1H),9.51(s,1H),8.11(s,1H),7.71(d,J=7.8Hz,1H),7.5 3(dt,J=13.0,7.8Hz,2H),7.36(d,J=8.0Hz,2H),7.09(d,J=8.0Hz,2H),3.99(s,4H),2.24(s,3H).ESI-MS m / z:

[0059] [M+1] calculated for C 17 H 18 N4O:294.3;found:294.9.

[0060] Example 6 Preparation of N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-methylphenyl)amino]methaneamide

[0061] The difference between this embodiment and embodiment 1 is that: in step (3), 3-methylphenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0062] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0063] The chemical structure of the obtained N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-methylphenyl)amino]methaneamide is as follows:

[0064]

[0065] 1 H NMR (400MHz, DMSO-d6) δ10.59(s,1H),9.78(s,1H),9.50(s,1H),8.13(t,J=2.0Hz,1H),7.71(d,J=8.0Hz,1H),7.53(dt ,J=16.8,7.8Hz,2H),7.34–7.24(m,2H),7.16(t,J=7.8Hz,1H),6.80(d,J=7.4Hz,1H),4.00(s,4H),2.28(s,3H).ESI-MS m / z:[M+1]calculated for C 17 H 18 N4O:294.3;found:294.9.

[0066] Example 7 Preparation of N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-methoxyphenyl)amino]methaneamide:

[0067] The difference between this embodiment and embodiment 1 is that: in step (3), 4-methoxyphenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0068] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0069] The chemical structure of the obtained N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-methoxyphenyl)amino]methaneamide is as follows:

[0070]

[0071] 1H NMR (400MHz, DMSO-d6) δ10.30(s,1H),9.66(s,1H),9.36(s,1H),8.09(d,J=2.0Hz,1H),7.73–7.66 (m,1H),7.56–7.45(m,2H),7.41–7.34(m,2H),6.92–6.84(m,2H),3.96(s,4H),3.72(s,3H).ESI-MS m / z:[M+1]calculated for C 17 H 18 N4O2:310.3; found:310.9.

[0072] Example 8 Preparation of N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-methoxyphenyl)amino]methaneamide:

[0073] The difference between this embodiment and embodiment 1 is that: in step (3), 3-methoxyphenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0074] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0075] The chemical structure of the obtained N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-methoxyphenyl)amino]methaneamide is as follows:

[0076]

[0077] 1 H NMR (400MHz, DMSO-d6) δ10.70(s,2H),9.99(s,1H),9.82(s,1H),8.11(d,J=2.3Hz,1H),7.73(dt,J=5.3,2.5Hz,1H),7.5 6(s,2H),7.27–7.14(m,2H),6.96(dd,J=7.9,1.9Hz,1H),6.56(dd,J=8.2,2.4Hz,1H),4.00(s,4H),3.73(s,3H).ESI-MS m / z:[M+1]calculated for C 17 H 18 N4O2:310.3; found:310.9.

[0078] Example 9 Preparation of 1-[(4-cyanophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide:

[0079] The difference between this embodiment and embodiment 1 is that: in step (3), 4-cyanophenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0080] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0081] The chemical structure of the obtained 1-[(4-cyanophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide is as follows:

[0082]

[0083] 1 H NMR (400MHz, DMSO-d6) δ10.55(s,1H),10.29(s,1H),9.96(s,1H),8.09(s,1H),7. 75(d,J=8.7Hz,3H),7.66(d,J=8.5Hz,2H),7.61–7.52(m,2H),4.00(s,4H).ESI-MS m / z:[M+1]calculated for C 17 H 15 N5O:305.3; found:305.9.

[0084] Example 10 Preparation of 1-[(3-cyanophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide:

[0085] The difference between this embodiment and embodiment 1 is that: in step (3), 3-cyanophenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0086] The other steps in this embodiment are the same as those in Embodiment 1 and will not be described again.

[0087] The chemical structure of the obtained 1-[(3-cyanophenyl)amino]-N-[3-(4,5-dihydro-3H-imidazol-2-yl)phenyl]methaneamide is as follows:

[0088]

[0089] 1H NMR (400MHz, DMSO-d6) δ10.53(s,1H),10.27(s,1H),10.01(s,1H),8.10(s,1H),8.02(t,J=1.8Hz,1H),7.75( td,J=4.7,2.2Hz,1H),7.66(dt,J=8.4,1.6Hz,1H),7.62–7.50(m,3H),7.50–7.40(m,1H),4.00(s,4H).ESI-MS m / z:[M+1]calculated forC 17 H 15 N5O:305.3; found:305.9.

[0090] Example 11 Preparation of 1-[(4-cyanophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide:

[0091] Step (1) 3-fluoro-5-nitrobenzaldehyde (2 mmol) and ethylenediamine (1.1 equivalents) were mixed with tert-butyl alcohol and stirred for 30 minutes, then Na2CO3 (3 equivalents) and I2 (1.25 equivalents) were added to the mixture, and the reaction temperature was raised to 70°C and continued to stir for 3 hours. After the reaction was completed, the reaction solvent tert-butyl alcohol was removed under reduced pressure. Ethyl acetate was added to the mixture, and the insoluble matter was removed by ultrasonication and filtration. The organic layer was washed with a saturated Na2SO3 aqueous solution and brine, and dried over anhydrous MgSO4. The resulting mixture was purified by column chromatography to obtain 2-(5-fluoro-3-nitrophenyl)-4,5-dihydro-3H-imidazole, the chemical structure of which is as follows:

[0092]

[0093] 1 H NMR (400MHz, DMSO-d6) δ8.51(t,J=1.7Hz,1H),8.24(dt,J=8.5,2.3Hz,1H),8.07(J=9.2,2.6,1.4Hz,1H),7.40(s,1H),3.68(s,4H).

[0094] Step (2) The 2-(5-fluoro-3-nitrophenyl)-4,5-dihydro-3H-imidazole obtained in the previous step is dissolved in methanol, and then 5 wt% palladium carbon is added, the reaction container is deoxygenated, and H2 is added through a balloon, and the reaction is carried out at room temperature overnight. The resulting mixture is filtered through diatomaceous earth, and the filtrate is evaporated to obtain 5-(4,5-dihydro-3H-imidazole-2-yl)-3-fluoroaniline, the chemical structure of which is as follows:

[0095]

[0096] 1 H NMR (400MHz, DMSO-d6) δ10.50(s,1H),6.89(dd,J=8.3,2.1Hz,2H),6.66(dt,J=11.5,2.1Hz,1H),5.96(s,2H),3.92(s,4H).

[0097] Step (3) To a stirred DMF solution of 5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluoroaniline (1 mmol) and triethylamine (2 equivalents) was added the corresponding 4-cyanophenyl isocyanate (1 equivalent), and the mixture was stirred at 60° C. for 5 hours. After the reaction was completed by thin layer chromatography, the mixture was extracted with dichloromethane, the organic phase was washed with saturated brine and dried over anhydrous MgSO4, and the organic phase was distilled under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain 1-[(4-cyanophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide, the chemical structure of which is as follows:

[0098]

[0099] 1 H NMR (400MHz, DMSO-d6) δ9.97(s,1H),9.89(s,1H),7.77–7.66(m,5H),7.62(dd,J=11.4,2.3Hz,1H),7.21(dd,J=9.6,2.3Hz,1H),3.67(s,4H).ESI-MS m / z:[M+1]calculated for C 17 H 14 FN5O:323.3; found:323.9.

[0100] Example 12 Preparation of 1-[(3-cyanophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide:

[0101] The difference between this embodiment and embodiment 11 is that: in step (3), 3-cyanophenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0102] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0103] The chemical structure of the obtained 1-[(3-cyanophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide is as follows:

[0104]

[0105] 1 H NMR(400MHz, DMSO-d6)δ9.93(d,J=7.9Hz,2H),8.00(s,1H),7.77–7.67(m,2H),7.62(d,J=11.3H z,1H),7.50(t,J=7.9Hz,1H),7.43(d,J=7.8Hz,1H),7.21(d,J=9.4Hz,1H),3.67(s,4H).ESI-MS m / z:[M+1]calculated for C 17 H 14 FN5O:323.3; found:323.9.

[0106] Example 13 Preparation of N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(4-fluorophenyl)amino]methaneamide:

[0107] The difference between this embodiment and embodiment 11 is that: in step (3), 4-fluorophenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0108] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0109] The chemical structure of the obtained N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(4-fluorophenyl)amino]methaneamide is as follows:

[0110]

[0111] 1 H NMR(400MHz,DMSO-d6)δ10.67(s,1H),9.81(s,1H),9.57(s,1H),7.81–7.71(m,2H),7.48(dd ,J=9.0,4.9Hz,2H),7.37(dt,J=8.9,2.0Hz,1H),7.15(t,J=8.9Hz,2H),4.00(s,4H).ESI-MS m / z:[M+1]calculated for C 16 H 14 F2N4O:316.3;found:317.0.

[0112] Example 14 Preparation of N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(3-fluorophenyl)amino]methaneamide:

[0113] The difference between this embodiment and embodiment 11 is that: in step (3), 3-fluorophenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0114] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0115] The chemical structure of the obtained N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(3-fluorophenyl)amino]methaneamide is as follows:

[0116]

[0117] 1 H NMR (400MHz, DMSO-d6) δ10.67(s,1H),9.86(d,J=19.7Hz,1H),9.76(d,J=22.0Hz,1H),7.82–7.69(m,2H),7.51(dt,J =11.9,2.4Hz,1H),7.41–7.25(m,2H),7.15(dd,J=8.2,1.9Hz,1H),6.83(td,J=8.5,2.6Hz,1H),4.01(s,4H).ESI-MS m / z:[M+1]calculated for C 16 H 14 F2N4O:316.3; found:316.9.

[0118] Example 15 Preparation of 1-[(4-chlorophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide:

[0119] The difference between this embodiment and embodiment 11 is that: in step (3), 4-chlorophenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0120] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0121] The chemical structure of the obtained 1-[(4-chlorophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide is as follows:

[0122]

[0123] 1H NMR(400MHz,DMSO-d6)δ10.00(s,1H),9.84(s,1H),7.70–7.61(m,2H),7.53(d,J=8.5Hz ,2H),7.32(d,J=8.6Hz,2H),7.18(dd,J=9.7,2.4Hz,1H),4.02(t,J=7.1Hz,4H).ESI-MS m / z:[M+1]calculated for C 16 H 15 ClFN4O:333.1;found:333.2.

[0124] Example 16 Preparation of 1-[(3-chlorophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide:

[0125] The difference between this embodiment and embodiment 11 is that: in step (3), 3-chlorophenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0126] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0127] The chemical structure of the obtained 1-[(3-chlorophenyl)amino]-N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]methaneamide is as follows:

[0128]

[0129] 1 H NMR (400MHz, DMSO-d6) δ9.01(s,1H),8.69(s,1H),7.59(d,J=13.0Hz,2H),7.34(d,J=8.1Hz,2H),7.13(dd,J=26.5,8.2Hz,3H),3.62(s,4H).ESI-MS m / z:[M+1]calculated for C 16 H 15 ClFN4O:333.1;found:333.2.

[0130] Example 17 Preparation of N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(4-methoxyphenyl)amino]methaneamide:

[0131] The difference between this embodiment and embodiment 11 is that: in step (3), 4-methoxyphenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0132] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0133] The chemical structure of the obtained N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(4-methoxyphenyl)amino]methaneamide is as follows:

[0134]

[0135] 1 H NMR (400MHz, DMSO-d6) δ10.61(s,1H),9.69(s,1H),9.24(s,1H),7.74(dd,J=24.8,13.6Hz, 2H),7.36(dd,J=13.6,8.7Hz,3H),6.89(d,J=8.6Hz,2H),4.00(s,4H),3.72(s,3H).ESI-MS m / z:[M+1]calculated for C 16 H 17 FN4O2:328.3; found:328.9.

[0136] Example 18 Preparation of N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(3-methoxyphenyl)amino]methaneamide:

[0137] The difference between this embodiment and embodiment 11 is that: in step (3), 3-methoxyphenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0138] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0139] The chemical structure of the obtained N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(3-methoxyphenyl)amino]methaneamide is as follows:

[0140]

[0141] 1 H NMR(400MHz,DMSO-d6)δ9.42(s,1H),9.18(s,1H),7.68–7.55(m,2H),7.24–7.14(m,3H),6.9 6(dd,J=8.0,1.9Hz,1H),6.57(dd,J=8.2,2.5Hz,1H),4.03,3.74(s,4H),3.64(s,3H).ESI-MS m / z:[M+1]calculated for C 16 H17 FN4O2:328.3; found:328.9.

[0142] Example 19 Preparation of N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(4-methylphenyl)amino]methaneamide:

[0143] The difference between this embodiment and embodiment 11 is that: in step (3), 4-methylphenyl isocyanate is used instead of 4-cyanophenyl isocyanate;

[0144] The other steps in this embodiment are the same as those in Embodiment 11 and will not be described again here.

[0145] The chemical structure of the obtained N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-fluorophenyl]-1-[(4-methylphenyl)amino]methaneamide is as follows:

[0146]

[0147] 1 H NMR (400MHz, DMSO-d6) δ9.03(s,1H),8.71(s,1H),7.60(d,J=1.9Hz,1H),7.57(t,J=2.2Hz,1H),7.3 6–7.32(m,2H),7.16(dt,J=9.5,2.1Hz,1H),7.10(d,J=8.2Hz,2H),3.62(s,4H),2.25(s,3H).ESI-MS m / z:[M+1]calculated for C17H18FN4O:313.1; found:312.9.

[0148] Example 20 Preparation of N-[3-bromo-5-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-fluorophenyl)amino]methaneamide:

[0149] Step (1) 3-bromo-5-nitrobenzaldehyde (2 mmol) and ethylenediamine (1.1 equivalents) were mixed with tert-butanol and stirred for 30 minutes, then Na2CO3 (3 equivalents) and I2 (1.25 equivalents) were added to the mixture, and the reaction temperature was raised to 70°C and stirring was continued for 3 hours. After the reaction was completed, the reaction solvent tert-butanol was removed under reduced pressure, ethyl acetate was added to the mixture, and insoluble matter was removed by ultrasonication and filtration. The organic layer was washed with saturated Na2SO3 aqueous solution and brine, and dried over anhydrous MgSO4. The resulting mixture was purified by column chromatography to obtain 2-(5-bromo-3-nitrophenyl)-4,5-dihydro-3H-imidazole, the chemical structure of which is as follows:

[0150]

[0151] 1 H NMR (400MHz, DMSO-d6) δ8.62(dd,J=2.2,1.5Hz,1H),8.48(t,J=2.0Hz,1H),8.40(t,J=1.7Hz,1H),7.55(s,1H),3.66(s,4H).

[0152] Step (2) The 2-(5-bromo-3-nitrophenyl)-4,5-dihydro-3H-imidazole obtained in the previous step is dissolved in methanol, and then 5 wt% palladium carbon is added, the reaction container is deoxygenated, and H2 is added through a balloon, and the reaction is carried out at room temperature overnight. The resulting mixture is filtered through diatomaceous earth, and the filtrate is evaporated to obtain 3-bromo-5-(4,5-dihydro-3H-imidazole-2-yl)aniline, the chemical structure of which is as follows:

[0153]

[0154] 1 H NMR (400MHz, DMSO-d6) δ6.87(t,J=1.7Hz,1H),6.65(J=10.0,2.5,1.4Hz,1H),6.39(dt,J=11.5,2.3Hz,1H),5.53(s,2H),3.60(s,4H).

[0155] Step (3) To a stirred DMF solution of 3-bromo-5-(4,5-dihydro-3H-imidazol-2-yl)aniline (1 mmol) and triethylamine (2 equivalents) was added the corresponding 4-fluorophenyl isocyanate (1 equivalent), and the mixture was stirred at 60° C. for 5 hours. After the reaction was completed by thin layer chromatography, the mixture was extracted with dichloromethane, the organic phase was washed with saturated brine and dried over anhydrous MgSO4, and the organic phase was distilled under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain N-[3-bromo-5-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(4-fluorophenyl)amino]methaneamide, the chemical structure of which is as follows:

[0156]

[0157] 1 H NMR (400MHz, DMSO-d6) δ10.65(s,1H),9.82(s,1H),9.56(s,1H),8.06(t,J=1.9Hz,1H),7.96(t,J=1.7Hz,1H),7.69(t,J=1.7Hz,1H),7.52–

[0158] 7.45(m,2H),7.18–7.12(m,2H),4.00(s,4H).ESI-MS m / z:[M+1]calculated forC 16 H 14 BrFN4O:376.0;found:376.8.

[0159] Example 21 Preparation of N-[3-bromo-5-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-fluorophenyl)amino]methaneamide:

[0160] The difference between this embodiment and embodiment 20 is that: in step (3), 3-fluorophenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0161] The other steps in this embodiment are the same as those in Embodiment 20 and will not be repeated here.

[0162] The chemical structure of the obtained N-[3-bromo-5-(4,5-dihydro-3H-imidazol-2-yl)phenyl]-1-[(3-fluorophenyl)amino]methaneamide is as follows:

[0163]

[0164] 1 H NMR (400MHz, DMSO-d6) δ9.82(s,1H),9.74(s,1H),8.04(d,J=1.9Hz,1H),7.97(s,1H),7.70(s,1H),7.51(dt,J=1 1.9, 2.4Hz, 1H), 7.35–7.29 (m, 1H), 7.15 (dd, J=8.1, 1.9Hz, 1H), 6.83 (td, J=8.5, 2.6Hz, 1H), 3.98 (s, 4H).ESI-MS m / z:[M+1]calculated forC 16 H 14 BrFN4O:376.0;found:376.8.

[0165] Example 22 Preparation of N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-methoxyphenyl]-1-[(4-fluorophenyl)amino]methaneamide:

[0166] Step (1) 3-methoxy-5-nitrobenzaldehyde (2 mmol) and ethylenediamine (1.1 equivalents) were mixed with tert-butanol and stirred for 30 minutes, then Na2CO3 (3 equivalents) and I2 (1.25 equivalents) were added to the mixture, and the reaction temperature was raised to 70°C and stirring was continued for 3 hours. After the reaction was completed, the reaction solvent tert-butanol was removed under reduced pressure, ethyl acetate was added to the mixture, and insoluble matter was removed by ultrasonication and filtration. The organic layer was washed with saturated Na2SO3 aqueous solution and brine, and dried over anhydrous MgSO4. The resulting mixture was purified by column chromatography to obtain 2-(5-methoxy-3-nitrophenyl)-4,5-dihydro-3H-imidazole, the chemical structure of which is as follows:

[0167]

[0168] 1 H NMR (400MHz, DMSO-d6) δ8.26 (t, J=1.7Hz, 1H), 7.81 (q, J=1.7, 1.1Hz, 2H), 3.92 (s, 3H), 3.68 (s, 4H).

[0169] Step (2) The 2-(5-methoxy-3-nitrophenyl)-4,5-dihydro-3H-imidazole obtained in the previous step is dissolved in methanol, and then 5wt% palladium carbon is added, the reaction container is deoxygenated, and H2 is added through a balloon, and the reaction is carried out at room temperature overnight. The resulting mixture is filtered through diatomaceous earth, and the filtrate is evaporated to obtain 5-(4,5-dihydro-3H-imidazole-2-yl)-3-methoxyaniline, the chemical structure of which is as follows:

[0170]

[0171] 1 H NMR (400MHz, DMSO-d6) δ6.65(t,J=1.7Hz,1H),6.61–6.51(m,1H),6.22(t,J=2.2Hz,1H),5.19(s,2H),3.68(s,3H),3.56(s,4H).

[0172] Step (3) To a stirred DMF solution of 5-(4,5-dihydro-3H-imidazol-2-yl)-3-methoxyaniline (1 mmol) and triethylamine (2 equivalents) was added the corresponding 4-fluorophenyl isocyanate (1 equivalent), and the mixture was stirred at 60° C. for 5 hours. After the reaction was completed by thin layer chromatography, the mixture was extracted with dichloromethane, the organic phase was washed with saturated brine and dried over anhydrous MgSO4, and the organic phase was distilled under reduced pressure to obtain a crude product, which was purified by column chromatography to obtain N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-methoxyphenyl]-1-[(4-fluorophenyl)amino]methaneamide, the chemical structure of which is as follows:

[0173]

[0174] 1 H NMR(400MHz,DMSO-d6)δ9.09(s,1H),9.04(s,1H),7.48(dd,J=8.9,5.0Hz,2H),7.42(s,1H), 7.32(s,1H),7.12(t,J=8.9Hz,2H),6.99(d,J=2.5Hz,1H),3.77(s,3H),3.63(s,4H).ESI-MS m / z:[M+1]calculated for C 17 H 18 FN4O2:329.1; found:329.2.

[0175] Example 23 Preparation of N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-methoxyphenyl]-1-[(3-fluorophenyl)amino]methaneamide:

[0176] The difference between this embodiment and embodiment 22 is that: in step (3), 3-fluorophenyl isocyanate is used instead of 4-fluorophenyl isocyanate;

[0177] The other steps in this embodiment are the same as those in Embodiment 22 and will not be repeated here.

[0178] The chemical structure of the obtained N-[5-(4,5-dihydro-3H-imidazol-2-yl)-3-methoxyphenyl]-1-[(3-fluorophenyl)amino]methaneamide is as follows:

[0179]

[0180] 1H NMR (400MHz, DMSO-d6) δ10.52(s,1H),9.62(s,1H),9.56(s,1H),7.61(d,J=1.8Hz,1H),7.50(dt,J=12.0,2.3Hz,1H),7.41(t,J= 2.1Hz,1H),7.32(td,J=8.2,6.8Hz,1H),7.14(J=4.6,2.0Hz,2H),6.81(td,J=8.5,2.6Hz,1H),4.00(s,4H),3.83(s,3H).ESI-MS m / z:[M+1]calculated for C 17 H 18 FN4O2:329.1; found:329.2.

[0181] Experimental example

[0182] Preparation of Babesia strains for testing:

[0183] The parasite strains tested in this experimental example involved Babesia gibsoni.

[0184] Components and preparation of Babesia culture medium:

[0185] Components of the basic culture medium for Babesia gibbsii and its preparation method: Prepare 1000 ml of SFM basic culture medium (VP-SFM ATG 12559-019 17.6 g, Albumax I 2 g, L-glutamine 200 mM (Sigma) 20 mL, Antibiotic / Antimycotic 10 mL (100×), dd-H2O 970 mL). When used, take 47.5 mL of SFM culture medium into a 50 mL centrifuge tube and add 2.5 ml of self-collected canine serum (from beagle dogs). This liquid culture medium is a typical liquid culture medium for Babesia gibbsii. The above operations are all performed in the sterile environment of a conventional cell-room clean bench.

[0186] Preparation of test compounds:

[0187] The compounds of Examples 1-23 were used as solutions. Dimethyl sulfoxide (DMSO), 10× phosphate buffered saline (10× PBS) and SFM culture medium were used to dissolve the inhibitor powder for subsequent experiments. Specific preparation method: First, a compound concentrate with an original concentration of 100 mM was prepared for storage and then diluted with 10× PBS to an intermediate concentration (200 μM). When determining the half-maximal inhibitory concentration of the compound against Babesia gibbsii, the prepared inhibitor concentrate was diluted with SFM culture medium for a concentration gradient experiment, and the concentration gradients were designed to be: 0.1, 1, 10, 50 μM.

[0188] Babesia culture method:

[0189] Babesia gibbsii: In a 48-well culture plate, add the conventional culture system of Babesia gibbsii (50 μL red blood cells, 450 μL Babesia gibbsii culture medium (SFM culture medium containing canine serum)), place in a 5% CO2 incubator, and culture at 37°C. Change the medium every 24 hours (absorb 400 μL culture medium, add 400 μL new culture medium) and mix thoroughly with the red blood cells at the bottom, and passage once every 72 hours (after fully mixing the old well, aspirate 50 μL and add it to the new well, then add 45 μL fresh canine red blood cells and 405 μL Babesia gibbsii culture medium).

[0190] In vitro growth inhibition test of Babesia gibsoni

[0191] Inhibition test for Babesia gibbsii: According to the aseptic operation procedure, 0.3 μL of red blood cell mud was drawn from the 48-well culture plate of Babesia, and a blood smear was made. After Giemsa staining, the infection rate was observed under a microscope. The infection rate was diluted to 0.2% with red blood cells from healthy dogs. The mixture was fully mixed with SFM culture medium and evenly divided into a new 96-well culture plate according to a volume of 50 μL per well. The candidate inhibitors were taken and three replicates were performed for each concentration. The mixture in each well was fully mixed and cultured at 37°C for 72 hours. The infection rate was counted, the effect of the compound on the in vitro growth of Babesia gibbsii was observed, and the half-maximal inhibitory concentration (IC50) was calculated. The entire operation was carried out under the aseptic operation procedure of the commonly used cell-to-cell clean bench.

[0192] The test results of compound activity data are shown in Table 1:

[0193] Table 1

[0194] <![CDATA[IC 50 (μM)]]> Example <![CDATA[IC 50 (μM)]]> Example 1 >50 Example 13 <![CDATA[10<IC 50 <50]]> Example 2 <![CDATA[1<IC 50 <10]]> Embodiment 14 <![CDATA[10<IC 50 <50]]> Example 3 <![CDATA[10<IC 50 <50]]> Embodiment 15 <![CDATA[10<IC 50 <50]]> Example 4 <![CDATA[10<IC 50 <50]]> Example 16 <![CDATA[10<IC 50 <50]]> Example 5 <![CDATA[10<IC 50 <50]]> Embodiment 17 >50 Example 6 <![CDATA[1<IC 50 <10]]> Embodiment 18 <![CDATA[10<IC 50 <50]]> Example 7 >50 Embodiment 19 <![CDATA[1<IC 50 <10]]> Example 8 <![CDATA[10<IC 50 <50]]> Embodiment 20 <![CDATA[10<IC 50 <50]]> Example 9 <![CDATA[1<IC 50 <10]]> Embodiment 21 <![CDATA[10<IC 50 <50]]> Example 10 <![CDATA[1<IC 50 <10]]> Embodiment 22 >50 Embodiment 11 <![CDATA[10<IC 50 <50]]> Embodiment 23 <![CDATA[10<IC 50 <50]]> Example 12 <![CDATA[10<IC 50 <50]]>

[0195] From the test results in Table 1, it can be seen that the half-maximal inhibitory concentration of the compounds prepared in Examples 1-23 of the present invention on Babesia gibbsii can reach as low as 1 μM <IC 50 <10 μM, indicating that the asymmetric urea small molecule compound and its derivatives of the present invention have good anti-Babesia activity.

[0196] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. Use of an asymmetric urea small molecule compound in the preparation of a drug for treating babesiosis, characterized in that: The asymmetric urea small molecule compound is selected from the following structural formula:

Citation Information

Patent Citations

  • Type iii secretion inhibitors, analogs and uses thereof

    WO2009145829A1

  • Benzimidazoles for the treatment of cancer

    WO2014027053A1